$REED
REED'S, INC. Stock $reed

$reed Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223019742 Filed on June 01, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$10.01M	$11.16M	$12.18M
YoY Change	-27.1%	-8.41%	0.26%
Cost Of Revenue	$7.496M	$8.459M	$9.250M
YoY Change	-28.1%	-8.55%	11.58%
Gross Profit	$2.509M	$2.698M	$2.932M
YoY Change	-23.95%	-7.98%	-23.84%
Gross Profit Margin	25.08%	24.18%	24.07%
Selling, General & Admin	$2.570M	$3.156M	$4.299M
YoY Change	-35.8%	-26.59%	-10.81%
% of Gross Profit	102.43%	116.98%	146.62%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$32.00K	$47.00K	$25.00K
YoY Change	23.08%	88.0%	-58.33%
% of Gross Profit	1.28%	1.74%	0.85%
Operating Expenses	$4.256M	$5.276M	$7.111M
YoY Change	-45.68%	-25.81%	-12.32%
Operating Profit	-$1.747M	-$2.578M	-$4.179M
YoY Change	-61.49%	-38.31%	-1.9%
Interest Expense	$1.387M	$1.779M	-$801.0K
YoY Change	156.38%	-322.1%	208.08%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$3.134M	-$4.357M	-$4.980M
YoY Change	-38.27%	-12.51%	10.42%
Income Tax
% Of Pretax Income
Net Earnings	-$3.134M	-$4.357M	-$4.980M
YoY Change	-38.27%	-12.51%	10.42%
Net Earnings / Revenue	-31.32%	-39.05%	-40.88%
Basic Earnings Per Share	-$0.99	-$1.70	-$2.56
Diluted Earnings Per Share	-$0.99	-$1.70	-$51.14K
COMMON SHARES
Basic Shares Outstanding	2.602M shares	2.602M shares	1.948M shares
Diluted Shares Outstanding	3.180M shares	2.560M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$447.0K	$467.0K	$122.0K
YoY Change	59.64%	282.79%	-23.75%
Cash & Equivalents	$447.0K	$467.0K	$122.0K
Short-Term Investments
Other Short-Term Assets	$880.0K	$601.0K	$1.561M
YoY Change	-38.89%	-61.5%	-26.02%
Inventory	$13.69M	$15.30M	$20.85M
Prepaid Expenses
Receivables	$3.734M	$4.665M	$5.161M
Other Receivables	$777.0K	$777.0K	$1.135M
Total Short-Term Assets	$19.53M	$21.81M	$28.83M
YoY Change	-43.59%	-24.34%	41.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$543.0K	$686.0K	$940.0K
YoY Change	-38.64%	-27.02%	-1.05%
Goodwill
YoY Change
Intangibles	$678.0K	$676.0K
YoY Change	0.89%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.170M	$1.312M	$1.564M
YoY Change	-22.47%	-16.11%	-4.63%
TOTAL ASSETS
Total Short-Term Assets	$19.53M	$21.81M	$28.83M
Total Long-Term Assets	$1.170M	$1.312M	$1.564M
Total Assets	$20.70M	$23.12M	$30.39M
YoY Change	-42.71%	-23.91%	37.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.201M	$11.17M	$16.36M
YoY Change	-43.21%	-31.75%	101.22%
Accrued Expenses	$798.0K	$467.0K	$856.0K
YoY Change	8.28%	-45.44%	45.08%
Deferred Revenue
YoY Change
Short-Term Debt	$6.560M	$7.593M	$7.475M
YoY Change	-40.87%	1.58%	75.47%
Long-Term Debt Due	$7.241M	$5.485M
YoY Change	305.43%
Total Short-Term Liabilities	$23.11M	$26.76M	$25.43M
YoY Change	-16.86%	5.26%	72.37%
LONG-TERM LIABILITIES
Long-Term Debt	$8.945M	$8.526M	$0.00
YoY Change	5.97%		-100.0%
Other Long-Term Liabilities	$103.0K	$156.0K	$350.0K
YoY Change	-66.12%	-55.43%	-32.69%
Total Long-Term Liabilities	$9.048M	$8.682M	$350.0K
YoY Change	3.46%	2380.57%	-37.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.11M	$26.76M	$25.43M
Total Long-Term Liabilities	$9.048M	$8.682M	$350.0K
Total Liabilities	$32.16M	$35.45M	$25.78M
YoY Change	-12.0%	37.52%	68.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$130.7M	-$127.6M
YoY Change	15.46%
Common Stock	$0.00	$0.00
YoY Change	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.46M	-$12.32M	$4.616M
YoY Change
Total Liabilities & Shareholders Equity	$20.70M	$23.12M	$30.39M
YoY Change	-42.71%	-23.91%	37.64%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.134M	-$4.357M	-$4.980M
YoY Change	-38.27%	-12.51%	10.42%
Depreciation, Depletion And Amortization	$32.00K	$47.00K	$25.00K
YoY Change	23.08%	88.0%	-58.33%
Cash From Operating Activities	-$3.405M	$1.117M	-$2.207M
YoY Change	-75.89%	-150.61%	-56.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$67.00K	$0.00	$0.00
YoY Change
Cash From Investing Activities	$67.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.318M	-$1.183M	2.280M
YoY Change	-76.77%	-151.89%	-51.69%
NET CHANGE
Cash From Operating Activities	-3.405M	$1.117M	-2.207M
Cash From Investing Activities	67.00K
Cash From Financing Activities	3.318M	-$1.183M	2.280M
Net Change In Cash	-20.00K	-$66.00K	$0.00
YoY Change	-112.66%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.405M	$1.117M	-$2.207M
Capital Expenditures
Free Cash Flow		$1.117M	-$2.207M
YoY Change		-150.61%	-55.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001140215
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2023Q1	REED	Fair Value Of Common Shares Issued As Financing Costs FairValueOfCommonSharesIssuedAsFinancingCosts		usd
CY2022Q1	REED	Accrual Of Interest On Convertible Note AccrualOfInterestOnConvertibleNote		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-32501
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	REED’S, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2177773
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 Merritt 7
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Norwalk
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06851
CY2023Q1	dei	City Area Code CityAreaCode	(800)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	997-3337
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2602399	shares
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash Cash	467000	usd
CY2022Q4	us-gaap	Cash Cash	533000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	213000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	252000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4665000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5671000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	15301000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	16175000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	601000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	939000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	21811000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	24095000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	867000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	787000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	686000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	766000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	626000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	626000	usd
CY2023Q1	us-gaap	Assets Assets	23123000	usd
CY2022Q4	us-gaap	Assets Assets	25487000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11165000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9805000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	233000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	322000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	363000	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	7593000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	10974000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	670000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	414000	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5485000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2434000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	194000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	187000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26763000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25658000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	484000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	562000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	8526000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	8092000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	156000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	35445000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	33957000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	10
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	10
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9411	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	9411	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	9411	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	9411	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	94000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	94000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2602399	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2602399	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2519485	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2519485	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	115140000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	114635000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127556000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123199000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12322000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8470000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23123000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25487000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11157000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12182000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8459000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9250000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2698000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	2932000	usd
CY2023Q1	REED	Delivery And Handling Expense DeliveryAndHandlingExpense	2120000	usd
CY2022Q1	REED	Delivery And Handling Expense DeliveryAndHandlingExpense	2812000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1447000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2178000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1709000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2121000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5276000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7111000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2578000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4179000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1779000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	801000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4980000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.56
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2559855	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1947548	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8470000	usd
CY2023Q1	REED	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Vested AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsVested	229000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	4000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	273000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12322000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4203000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4203000	usd
CY2022Q1	REED	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Vested AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsVested	225000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	66000	usd
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	37000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5067000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4980000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4616000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4616000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4980000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	281000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	65000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	431000	usd
CY2023Q1	REED	Fair Value Of Vested Options FairValueOfVestedOptions	-229000	usd
CY2022Q1	REED	Fair Value Of Vested Options FairValueOfVestedOptions	-225000	usd
CY2023Q1	REED	Fair Value Of Vested Restricted Shares Granted To Officers FairValueOfVestedRestrictedSharesGrantedToOfficers	-4000	usd
CY2022Q1	REED	Fair Value Of Vested Restricted Shares Granted To Officers FairValueOfVestedRestrictedSharesGrantedToOfficers	-66000	usd
CY2022Q1	REED	Fair Value Of Common Shares Issued As Financing Costs FairValueOfCommonSharesIssuedAsFinancingCosts	37000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-39000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	62000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	-228000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	10000	usd
CY2023Q1	REED	Accrual Of Interest On Convertible Note AccrualOfInterestOnConvertibleNote	1113000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1044000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	40000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1102000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3810000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-338000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	617000	usd
CY2023Q1	REED	Increase Decrease In Amortization Of Right Of Use Assets IncreaseDecreaseInAmortizationOfRightOfUseAssets	32000	usd
CY2022Q1	REED	Increase Decrease In Amortization Of Right Of Use Assets IncreaseDecreaseInAmortizationOfRightOfUseAssets	27000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1360000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5926000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	235000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	403000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1117000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2207000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	8699000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	14508000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	12120000	usd
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	17212000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2405000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5067000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-166000	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-81000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1183000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2280000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-66000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	73000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	533000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	49000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	467000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	122000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	390000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	256000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12322000	usd
CY2023Q1	us-gaap	Cash Cash	467000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	62000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	5084000	usd
CY2023Q1	REED	Carrying Cost Property And Exploration Rights CarryingCostPropertyAndExplorationRights	3.46	pure
CY2022Q1	REED	Carrying Cost Property And Exploration Rights CarryingCostPropertyAndExplorationRights	3.90	pure
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50 reverse stock split
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zIV9whzmHNF3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zWsVc4Z17RCi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing stock instruments issued for services, and assumptions used in valuing warrant liabilities, and assumptions used in the determination of the Company’s liquidity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1669360000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	487898000	shares
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	55000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	312000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zSJNEYtSF8th" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zzuqbLkSRs0c">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net sales.</i> During the three months ended March 31, 2023, the Company’s two largest customers accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zhjWD7A0vtC3" title="Concentration risk percentage">18</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8PY15ZIt8F7" title="Concentration risk percentage">13</span>% of net sales, respectively. During the three months ended March 31, 2022, the Company’s two largest customers accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zQRhjXHwYAJe" title="Concentration risk percentage">18</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zu6OK4kd7j5e" title="Concentration risk percentage">12</span>% of net sales, respectively. No other customers exceeded 10% of net sales in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts receivable.</i> As of March 31, 2023, the Company had accounts receivable from two customers which comprised <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkZGEPpt3xm" title="Concentration risk, percentage">18</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFMIAIE4P3W7" title="Concentration risk, percentage">11</span>% of its gross accounts receivable. As of December 31, 2022, the Company had accounts receivable from two customers which comprised <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPU0rP4JquH2" title="Concentration risk, percentage">19</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzI3sj3WGlrl" title="Concentration risk, percentage">11</span>% of its gross accounts receivable, respectively. No other customers exceeded 10% of gross accounts receivable in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2023 and the year ended December 31, 2022, the Company utilized six separate co-packers for most its production and bottling of beverage products in the United States. The Company utilizes co-packers to produce <span id="xdx_90A_ecustom--PercentageOfCoPackersProducts_pid_dp_uPure_c20230101__20230331_zRozQ453RjIh" title="Percentage of co-packers products">100</span>% of its products. The Company has long-standing relationships with two different co-packers, and in conjunction with the sale of its manufacturing plant we entered into a third co-packing agreement with California Custom Beverage LLC (“CCB”), the purchaser of the plant (see Note 11). CCB is <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__srt--TitleOfIndividualAxis__custom--ChristopherJReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zBn8F4bDgPEg" title="Concentration risk, percentage">100</span>% owned by Chris Reed, founder of the Company and formerly Chief Executive Officer, Chairman, director, and most recently, Chief Innovation Officer. Although there are other packers, a change in co-packers may cause a delay in the production process, which could ultimately affect operating results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchases from vendors.</i> During the three months ended March 31, 2023, the Company’s largest vendor accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zPrrhxezrSk2" title="Percentage of sale accounted to customer">11</span>% of all purchases. During the three months ended March 31, 2022, the Company’s largest vendor accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zXFarhHr1lO4" title="Percentage of sale accounted to customer">13</span>% of all purchases. No other vendors exceeded 10% of all purchases in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	REED	Percentage Of Co Packers Products PercentageOfCoPackersProducts	1	pure
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	7178000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8526000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8123000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7649000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	15301000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	16175000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1553000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1553000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	867000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	787000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	686000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	766000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	47000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	25000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	32000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	27000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	8526000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	8092000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2025-05-09
CY2023Q1	REED	Provision For Receivable With Former Related Party ProvisionForReceivableWithFormerRelatedParty	538000	usd
CY2023Q1	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	576000	usd
CY2022Q4	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	576000	usd
CY2023Q1	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	50000	usd
CY2022Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	50000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	626000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	626000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	322000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	363000	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	7593000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	10974000	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	13000000	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	10450000	usd
CY2023Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	2165000	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	1052000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1154000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	976000	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	14011000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	10526000	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5485000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2434000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	32000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	27000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	394000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	44000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	350000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M3D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1260	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	5016	shares
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	4.50
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	32000	usd
CY2023Q1	us-gaap	Share Price SharePrice	4.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.82	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0359	pure
CY2022	REED	Provision For Receivable With Former Related Party ProvisionForReceivableWithFormerRelatedParty	538000	usd
CY2023Q1	REED	Provision For Receivable With Former Related Party ProvisionForReceivableWithFormerRelatedParty	538000	usd
CY2022	REED	Provision For Receivable With Former Related Party ProvisionForReceivableWithFormerRelatedParty	538000	usd

Files In Submission

Name	View Source	Status
0001493152-23-019742-index-headers.html	Edgar Link	pending
0001493152-23-019742-index.html	Edgar Link	pending
0001493152-23-019742.txt	Edgar Link	pending
0001493152-23-019742-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
reed-20230331.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
reed-20230331_lab.xml	Edgar Link	unprocessable
reed-20230331_pre.xml	Edgar Link	unprocessable
reed-20230331_def.xml	Edgar Link	unprocessable
reed-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REED
REED'S, INC. Stock $reed

2023 Q2 Form 10-Q Financial Statement

#000149315223019742 Filed on June 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REED REED'S, INC. Stock $reed

2023 Q2 Form 10-Q Financial Statement

#000149315223019742 Filed on June 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REED
REED'S, INC. Stock $reed